• Who we are
Our mission
Our mission

Bring native bispecific therapeutics to patients

Our antibody development roots go deep

CD47 targeting
CD47 targeting

Safe and selective blockade of CD47 on tumors

Safe and selective blockade of CD47 on tumors

CD28 targeting

Safe and selective CD28 co-stimulation

Safe and selective blockade of CD47 on tumors

Who we are
Who we are

Our antibody development roots go deep

Our antibody development roots go deep

Our technology
Our technology, natural bispecific antibodies

Multispecific yet natural

κλ bodies

Looking into the future
Looking into the future

Beyond bispecific antibodies

Beyond bispecific antibodies

previous arrow
next arrow
  • CD28 targeting
  • How it works

Ready for your next adventure?

Join our team to invent new therapies and help patients.

Our technology

κλ bodies, truly human

Native, non-engineered, human bispecific antibodies maintain human antibody sequence and structure.

A κλ body consists of:

  • 2 identical heavy chains
  • 2 different light chains: one kappa (κ) and one lambda (λ)

kl bodies truly human 1

 

 

κλ body discovery, a simple process

We first identify antibodies using our common heavy chain antibody libraries. Then, we simply co-express one heavy chain and the two light chains. The bispecific κλ bodies can be directly tested using the cell culture supernatant or easily purified using standard affinity chromatography.

This process ensures a unique level of bsAb purity and integrity

High throughput bsAb screening

Fixed VH Diversified VLs

  • This process ensures a unique level of bsAb purity and integrity

  • High throughput bsAb screening

  • Fixed VH Diversified VLs

Don't miss any career opportunities and follow us now on LinkedIn

New publication in MABS 2024

Structural analysis of light chain-driven bispecific antibodies targeting CD47 andPD-L1

Read more

LinkedIn